BioNTech mRNA Cancer Therapy Misses Trial’s First Main Goal
BioNTech said its experimental mRNA cancer immunotherapy failed to meet the first main goal of a mid-to-late-stage trial in patients with head and neck cancer. Its US-listed shares were down nearly 3% in early trading.
BioNTech said on Tuesday that its experimental mRNA cancer immunotherapy did not meet the first main goal in a mid-to-late-stage trial involving patients with head and neck cancer. Shares of the drug developer listed in the US fell nearly 3% in early trading.